Imprimer

Articles médicaux - 2020

Écrit par Paul Coppo
ARTICLE EN FRANÇAIS
La maladie thrombo-embolique veineuse au cours du purpura thrombotique thrombocytopénique autoimmun est associée à un traitement prolongé par échanges plasmatiques [Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange]. Benhamou Y, Sauvètre G, Grangé S, Veyradier A, Coppo P. Rev Med Interne. 2020 Jul 27:S0248-8663(20)30225-3. French. doi: 10.1016/j.revmed.2020.06.014. Epub ahead of print. PMID: 32727695.
ARTICLES EN ANGLAIS
Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. Barba C, Peyre M, Galicier L, Cathebras P, Ranta D, Malot S, Veyradier A, Coppo P. Br J Haematol. 2020 Nov 20. doi: 10.1111/bjh.17170. Epub ahead of print. PMID: 33216951.
A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Charvet Rumpler A, De Witte S, Krummel T, Veyradier A, Benhamou Y. Blood. 2020 Nov 4:blood.2020008021. doi: 10.1182/blood.2020008021. Epub ahead of print. PMID: 33150928.
Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab. Mellaza C, Henry N, Fayolle PM, Mortaza S, Subra JF, Veyradier A, Coppo P, Augusto JF. Front Med (Lausanne). 2020 Oct 22;7:549931. doi: 10.3389/fmed.2020.549931. PMID: 33195299; PMCID: PMC7649819.
Efficacy of subcutaneous preemptive rituximab in immune-mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. Delrue M, Baylatry MT, Joly AC, Corre E, Marjanovic Z, El-Khoury-Hanna N, Féger F, Suner L, Veyradier A, Stépanian A, Coppo P. Am J Hematol. 2020 Oct 17. doi: 10.1002/ajh.26022. Epub ahead of print. PMID: 33068040.
HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children. Joly BS, Loiseau P, Darmon M, Leblanc T, Chambost H, Fouyssac F, Guigonis V, Harambat J, Stepanian A, Coppo P, Veyradier A. Haematologica. 2020 Jan 16;105(10):241968. doi: 10.3324/haematol.2019.241968. Epub ahead of print. PMID: 31949018; PMCID: PMC7556652.
Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura. Pereira LCV, Ercig B, Kangro K, Jamme M, Malot S, Galicier L, Poullin P, Provôt F, Presne C, Kanouni T, Servais A, Benhamou Y, Daguindau N, Vanhoorelbeke K, Azoulay E, Veyradier A, Coppo P. Hemasphere. 2020 Aug 11;4(4):e462. doi: 10.1097/HS9.0000000000000462. PMID: 32885148; PMCID: PMC7430230.
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Roose E, Schelpe AS, Tellier E, Sinkovits G, Joly BS, Dekimpe C, Kaplanski G, Le Besnerais M, Mancini I, Falter T, Von Auer C, Feys HB, Reti M, Rossmann H, Vandenbulcke A, Pareyn I, Voorberg J, Greinacher A, Benhamou Y, Deckmyn H, Fijnheer R, Prohászka Z, Peyvandi F, Lämmle B, Coppo P, De Meyer SF, Veyradier A, Vanhoorelbeke K. Blood. 2020 Jul 16;136(3):353-361. doi: 10.1182/blood.2019004221. PMID: 32356859.
Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F. J Thromb Haemost. 2020 Feb;18(2):479-484. doi: 10.1111/jth.14679. Epub 2019 Dec 9. PMID: 31691462; PMCID: PMC7027866.
Mis à jour le 23 Novembre 2020

Le CNR-MAT souhaite vous offrir la meilleure expérience possible sur son site. En poursuivant votre navigation, vous acceptez l’utilisation des cookies permettant d'étudier l’audience du site et de vous proposer du contenu et des services adaptés à votre intérêt pour les MAT. Pour en savoir plus, consultez notre politique cookies

J'accepte les cookies sur ce site